[Ip-health] BMJ series on fair pricing of medicines

Suerie Moon suerie.moon at gmail.com
Tue Jan 14 09:39:54 PST 2020


Dear ip-health,
Yesterday the BMJ published a 7-article series on fair pricing of
medicines, which presents work done by WHO and it's advisory committee on
the Fair Pricing Forum. Your comments are welcome:

Full series available here: https://www.bmj.com/fair-pricing
>From BMJ [starts]:
*Editorial*


*Can affordability and innovation coexist for medicines?
<https://www.bmj.com/content/368/bmj.l7058>**Improved transparency is
essential to determine what is fair writes Allison Colbert et al.*
*Analysis*


*Defining the concept of fair pricing for medicines
<https://www.bmj.com/content/368/bmj.l4726>**Suerie Moon and colleagues
consider what makes a fair price for both buyers and sellers*


*Strategies to achieve fairer prices for generic and biosimilar medicines
<https://www.bmj.com/content/368/bmj.l5444>**Early market entry and rapid
uptake of quality assured generic and biosimilars are key to improving
access to medicines, say Alessandra Ferrario and colleagues*


*Pricing of pharmaceuticals is becoming a major challenge for health
systems <https://www.bmj.com/content/368/bmj.l4627>**Manufacturers using
their market power to maximise profits results in prices that are
unjustifiable and unaffordable, argue Steven Morgan and colleagues*


*New business models for research and development with affordability
requirements are needed to achieve fair pricing of medicines
<https://www.bmj.com/content/368/bmj.l4408>**For research and development
to systematically deliver fairly priced medicines, new approaches to
financing and organisation are needed, and affordability must be integrated
into push, pull, and pooling mechanisms, say Fatima Suleman and colleagues*


*Price transparency is a step towards sustainable access in middle income
countries <https://www.bmj.com/content/368/bmj.l5375>**Tania Cernuschi and
colleagues show how information from the Market Information for Access to
Vaccines database is strengthening the ability of middle income countries
to negotiate with vaccine producers*
[ends]
best wishes,
Suerie

Suerie Moon, MPA, PhD
Co-Director, Global Health Centre, Graduate Institute of International and
Development Studies, Geneva
Adjunct Lecturer, Department of Global Health and Population, Harvard T.H.
Chan School of Public Health
suerie.moon at graduateinstitute.ch   Tel: +41-22-908-5845   Skype ID:
sueriemoon
Office:  Bureau P2-712, Maison de la Paix, Chemin Eugène-Rigot 2, 1202
Geneva, Switzerland.


More information about the Ip-health mailing list